Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283595 · ClinicalTrials.gov registry record · Phase 2
Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00283595: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00283595 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283595, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Decreased bone strength is a serious medical problem present in many women with Anorexia Nervosa, or disordered eating. Women with weaker bones are more likely to suffer broken bones than women with normal bone strength. We are investigating whether a hormone that is naturally produced by the human body, called growth hormone, can help strengthen the bones of women with this type of disordered eating.
Interventions
- DRUG Recombinant Human Growth Hormone
- DRUG Placebo for Recombinant Human Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283595
The ClinicalTrials.gov registry entry for NCT00283595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Recombinant Human Growth Hormone is the first listed.
NCT00283595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283595 about?
NCT00283595 is a clinical study titled "Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa". Decreased bone strength is a serious medical problem present in many women with Anorexia Nervosa, or disordered eating. Women with weaker bones are more likely to suffer broken bones than women with normal bone strength. We are investigating whether a hormone that is naturally produced by the human...
What is the current status of trial NCT00283595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2006-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00283595?
The interventions under investigation include: Recombinant Human Growth Hormone (DRUG), Placebo for Recombinant Human Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT00283595?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.